{"name":"LIQUIDIA TECH","slug":"liquidia-tech","ticker":"","exchange":"","domain":"liquidiatech.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"L606","genericName":"L606","slug":"l606","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"LIQ861 Inhaled Treprostinil","genericName":"LIQ861 Inhaled Treprostinil","slug":"liq861-inhaled-treprostinil","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"LIQ865A bupivacaine formulation","genericName":"LIQ865A bupivacaine formulation","slug":"liq865a-bupivacaine-formulation","indication":"Other","status":"phase_1"},{"name":"LIQ865B bupivacaine formulation","genericName":"LIQ865B bupivacaine formulation","slug":"liq865b-bupivacaine-formulation","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"L606","genericName":"L606","slug":"l606","phase":"phase_3","mechanism":"L606 is an inhaled dry powder formulation of treprostinil designed to deliver the prostacyclin analog directly to the lungs for pulmonary hypertension treatment.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"LIQ865A bupivacaine formulation","genericName":"LIQ865A bupivacaine formulation","slug":"liq865a-bupivacaine-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LIQ861 Inhaled Treprostinil","genericName":"LIQ861 Inhaled Treprostinil","slug":"liq861-inhaled-treprostinil","phase":"phase_3","mechanism":"LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"LIQ865B bupivacaine formulation","genericName":"LIQ865B bupivacaine formulation","slug":"liq865b-bupivacaine-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"phase_1":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}